SCHEMBL3490797

SCHEMBL3490797

COc1ccccc1N1C(=O)N(Cc2ccccc2)c2cc(Cl)cc(N3CCN(C)CC3)c2S1(=O)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.48
HCRTR2 O43614 1/20 0.48
DRD2 P14416 4/20 0.46
DRD3 P35462 3/20 0.46
DRD4 P21917 3/20 0.45
HRH2 P25021 2/20 0.45
HRH3 Q9Y5N1 1/20 0.45
HTR7 P34969 4/20 0.45
HTR1A P08908 2/20 0.45
HTR6 P50406 2/20 0.45
ADRA1B P35368 3/20 0.44
ADRA1D P25100 2/20 0.44
ADRA1A P35348 2/20 0.44
POLB P06746 1/20 0.43
MAPT P10636 2/20 0.43
UTS2R Q9UKP6 1/20 0.42
HTR2A P28223 1/20 0.42
HRH1 P35367 1/20 0.42
KDM4E B2RXH2 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3490332 0.91 HCRTR1 (0.47) HCRTR1HCRTR2DRD2DRD3HTR7
SCHEMBL3489094 0.86 HCRTR2 (0.53) HCRTR1HCRTR2MAPTTP53
SCHEMBL3488683 0.86 MAPT (0.48) HCRTR1HCRTR2MAPTKDM4ETP53
SCHEMBL3489218 0.86 HTT (0.52) HCRTR1HCRTR2ADRA1BADRA1DADRA1A
SCHEMBL3488417 0.86 HCRTR1 (0.43) HCRTR1HCRTR2DRD2DRD3DRD4
SCHEMBL3490201 0.85 HCRTR1 (0.47) HCRTR1HCRTR2DRD2DRD3HTR7
SCHEMBL3489592 0.83 MAPT (0.49) DRD2DRD3DRD4HTR1AADRA1B
SCHEMBL3490278 0.82 MAPT (0.48) HCRTR1HCRTR2ADRA1BADRA1DADRA1A
SCHEMBL3489300 0.81 MEN1 (0.42) HTR7HTR1AHTR6ADRA1BADRA1D
SCHEMBL3490206 0.80 MAPT (0.46) DRD2DRD3DRD4HTR1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D HCRTR1 131/4885HCRTR2 138/4885DRD2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.